Conference on Retroviruses and Opportunistic Infections (CROI) 2017, 13 - 16 February, 2017, Seattle
- Stopping secondary te prophylaxis in suppressed patients with cd4 100-200 is not safe: Jose Maria Miro Meda (poster)
2016 (accepted for presentation)
Conference on Retroviruses and Opportunistic Infections (CROI) 2016, 22 - 25 February, 2016, Boston, Massachusetts
1.CD4 Cell Response to First-line cART by HIV Type in European Cohort Collaborations. Linda Wittkop and Sophie Matheron for the COHERE in EuroCoord and ACHIeV2e study group (poster)
2.Risk of Kaposi Sarcoma in HIV-positive adults on ART: a global analyses. Eliane Rohner on behalf of COHERE in EuroCoord (poster)
3.Kaposi Sarcoma Risk in Children on ART from Africa, Europe and Asia. Eliane Rohner and Julia Bohlius on behalf of IeDEA SA, COHERE in EuroCoord, and TREAT Asia Pediatric HIV Observational Database (poster)
4.Global Burden of Cervical Cancer in HIV-Positive Women on ART. Eliane Rohner on behalf of IeDEA and COHERE in EuroCoord (poster & themed discussion)
5.Association of Tuberculosis with CD4 Recovery and HIV RNA Decline on ART in Europe. presented by Hansjakob Furrer on behalf of COHERE in EuroCoord (poster)
6.Safety of stopping T.gondii prophylaxis with suppressed viremia and CD4 >100 presented by Jose M Miro on behalf of COHERE in EuroCoord (poster)
21th Conference on Retroviruses and Opportunistic Infections, February 23 - 26, 2015, in Seattle, Washington
1 Immunodeficiency at the start of ART in children: A global view. K Panayidou and A Judd on behalf of the IeDEA and COHERE in EuroCoord Collaborations
2 Immunodeficiency at the start of ART: A global view. K Panayidou and O Kirk on behalf of the the IeDEA and COHERE in EuroCoord Collaborations
3 Reference curves for CD4 response to antiretroviral treatment in HIV-1 infected naïve patients. R Thiébaut on behalf of the Standard Reference Distribution of CD4 Working Group of COHERE in EuroCoord
4 Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV Infected Patients. H Bucher on behalf of COHERE in EuroCoord
5 Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings. S Ingle, Miro JM, Furrer H, Justice A, Saag M, Manzardo C, Esteve A, Sterne J, May M on behalf of COHERE in EuroCoord, CNICS and NA-ACCORD
EACS Conference, 21 - 24 October, 2015, in Barcelona, Spain
1. CD4+T-cell count at cART initiation among migrant men and women living in Western Europe Susana Monge on behalf of COHERE in EuroCoord. poster
2. Immunological and virological responses to combined antiretroviral treatment in male and female migrants in Europe; is benefit equal for all? Inma Jarrin on behalf of COHERE in EuroCoord. poster
1. Transient Viral Rebounds as a Prognostic Factor for Control Loss among 1075 HIV-controllers Followed in COHERE Collaboration Fanny Chereau on behalf of COHERE in EuroCoord. presentation
2. HIV Replication is a Major Predictor of Primary and Recurrent Pneumocystis Pneumonia - Implications for Prophylaxis Recommendations Hansjakob Furrer on behalf of COHERE in EuroCoord. presentation
3. HIV Viral Load as an Independent Risk Factor for Tuberculosis: the COHERE Collaboration Hansjakob Furrer on behalf of COHERE in EuroCoord.presentation
4. Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients? Lars Peters on behalf of COHERE in EuroCoord.presentation
15th ICMAOI, 26-27 October 2015, Bethesda, Maryland
Risk of Kaposi Sarcoma in HIV-positive Adults on ART: A Global Analysis. Bohlius J, Rohner E, Bütikofer L, Maskew M, Chen YM A, Fink V, Achenbach C, Egger M for International Epidemiologic Databases to Evaluate AIDS (IeDEA) and COHERE in EuroCoord.
10th AORTIC, 18 – 22 November 2015, Marrakech, Morocco
Kaposi sarcoma incidence rate in HIV-infected children on antiretroviral therapy from Southern Africa, Europe and Asia-Pacific. Rohner E and Bohlius J on behalf of COHERE in EuroCoord, IeDEA Southern Africa and IeDEA Asia-Pacific. In: 10th International African Organisation for Research and Training in Cancer Conference (AORTIC); November 18-22, 2015; Marrakech, Marocco.
HepHIV 2014 Conference: HIV and Viral Hepatitis: Challenges of Timely Testing and Care, 5-7 October 2014, Barcelona
Continued late presentation for HIV care across Europe. Amanda Mocroft on behalf of the Late Presenters Project Team of COHERE in EuroCoord. (oral)
International Workshop on Antiviral Drug Resistance, 3-7 June 2014, Berlin
Assessing the weight of mutations in the resistance of Darunavir/r in patients harbouring B subtype and non-B subtype virus. The joint COHERE-CHAIN project team for COHERE in EuroCoord. (poster)
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium
1 Response to combination antiretroviral treatment in HIV-positive individuals in Europe: variation by educational level. J del Amo for the socio-economic inequalities working group of COHERE in EuroCoord. presentation
2 Mortality in migrants living with HIV in Western European countries: differences by geographical origin and gender. S Monge on behalf of the migrants working group of COHERE in EuroCoord. presentation
3 Obese HIV-infected patients treated with efavirenz-containing regimens are at risk of virological failure. C Marzolini on behalf of the obesity working group of COHERE in EuroCoord. presentation
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June - 3 July, Kuala Lumpur
Late HIV diagnosis, late initiation of combination ART and mortality in Europe: variation by educations level. S Lodi on behalf of COHERE in EuroCoord.
Prevalence and impact of transmitted drug resistance (TDR) on response to ART in children. N Ngo-Giang-Huong and L Wittkop on behalf of EuroCoord-CHAIN-EPPICC project team.
20th Conference on Retroviruses and Opportunistic Infections, CROI 2013, 3-6 March 2013, Atlanta
The incidence of AIDS defining events (ADEs) at a current CD4 count ≥ 200/mm3 in the post combination antiretroviral therapy era. A Mocroft on behalf of the Opportunistic Infections Working Group of COHERE in EuroCoord. presentation
XIX International AIDS Conference, Washington D.C., 2012
1 Characteristics of individuals with HIV presenting late for care across Europe. J D. Lundgren for the late presenters working group of COHERE in EuroCoord.presentation (724 KB)
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome 2011
1 Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected patients with sustained viral response to cART. H C. Bucher on behalf of the OI working group of COHERE. presentation (175 KB)
18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011
1 HCV Treatment and CD4 Cell Count Decline in HIV/HCV Co-infected Patients: European Cohort Collaboration. C Smit, A d'Arminio, F de Wolf, M Puoti, F Dabis on behalf of the HCV working group of COHERE. poster (99 KB)
XVIII International AIDS Conference Vienna
1 Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy. L Wittkop on behalf of the EuroCoord-CHAIN joint project team.
2 PLATO II: Triple class virologic failure (TCVF) in HIV-infected children. K Butler on behalf of the PLATO II Project Team of COHERE
EACS Conference 11-14 November 2009 Cologne
1 CD4 count, viral suppression, prophylaxis and the risk of primary pneumocystis pneumonia in the cart era - the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A Mocroft, for the Opportunistic Infections Working Group.
2 Mortality rates of elderly HIV-infected adults treated with antiretroviral are closer to general population than in younger patients. C Lewden on behalf of COHERE.
1 Presence of drug resistance during the course of treatment in patients who developed virological failure to the three original classes of antiretroviral drug. Frank de Wolf on behalf of COHERE.
2 Viral load outcome after virologic failure of the three original antiretroviral drug classes in 2000-2007. Dominique Costagliola on behalf of COHERE.
3 HIV-related Hodgkin lymphoma in the era of HAART: incidence and survival in a European mulit-cohort study. Julia Bohlius on behalf of COHERE.
16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009
1 Risk of extensive triple class virologic failure of the three original antiretroviral drug classes among people followed from therapy initiation with NNRTI or ritonavir-boosted PI regimens. R Lodwick on behalf of the PLATO II project team of COHERE. Poster 159 KB
2 Impact of cART on Incidence and Prognosis of HIV-1-associated Non-Hodgkin-Lymphoma - European Multi-Cohort Study. J Bohlius, M Egger, on behalf of the COHERE study group. Poster 517 KB
14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 2007
1 Response to combination antiretroviral therapy (cART): variation by age.
CA Sabin for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Poster 528 as pdf file 216 KB